The FDA's Critical Path Initiative aims to speed drugs and medical devices from concept to cure and sees personalized medicine as one way to cut R&D costs and time. "We are on the verge of the most profound transformation in the history of medicine," FDA commissioner Dr. Andrew von Eschenbach said.

Related Summaries